12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Amatuximab regulatory update

FDA granted Orphan Drug designation for amatuximab from Eisai's Morphotek Inc. subsidiary to treat malignant pleural mesothelioma (MPM). In May, interim data...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >